The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical activity of BC2059, a novel compound that degrades beta-catenin, in colon cancer models.
Sunil Sharma
Employment or Leadership Position - Beta Cat Pharmaceuticals (U)
Stock Ownership - Beta Cat Pharmaceuticals
Research Funding - Beta Cat Pharmaceuticals
Raffaella Soldi
No relevant relationships to disclose
Glynn Weldon Gilcrease
No relevant relationships to disclose
Stephen Horrigan
Employment or Leadership Position - Beta Cat Pharmaceuticals
Stock Ownership - Beta Cat Pharmaceuticals